Work

From Sprinters to Marathoners: Rethinking Therapeutic Speed and Disease Modification in Atopic Dermatitis

Year: 2026

Type: article

Abstract: T. Bieber is/was speaker and/or consultant for AbbVie, Aclaris, Almirall, AnaptysBio, Apogee, Aristea, Attovia, Belenos, Biocryst, Biogeneration, BioVerSys, Bluefine, Böhringer-Ingelheim, Bristol-Myers Squibb, BYOME Labs, Cantargia, CellDex, Choate, Dermavant, DirigentBio, Domain Therapeutics, EMD Serono, EngImmune, Ennovate, Evommune, Forbion, Formycon, Galderma, Gilead, GSK, ImagGeneBio, Janssen, Kyowa/Kirin, Kymera, LEO, LG Chem, Lilly, Mabylon, MSD, Micreos, Nektar, Nextech, Novartis, Numab, Ornavi, Overtone, Pfizer, Pierre Fabre, Protagonist Tx, Samsung Bioepis, Sanofi/Regeneron, Scienta Lab, Serono, SwitchKine, TIRmed, Triton Therapeutics, Triveni, UCB, Union Therapeutics, UPStream Bio, WinWard, YUHAN, Zurabio. He is founder and chairman of the board of the non-profit biotech “Davos Biosciences AG” within the international Kühne-Foundation. He is also the founder and senior medical advisor of the consulting firm “Bieber Dermatology Consulting”. F. L is/was speaker and/or consultant for Abbvie, Almirall, Amgen, Biogen, Boehringer Inglheim, Bristol-Myers-Squibb, Janssen, Johnson & Johnson LEO Pharma, Lilly, Incyte, Novartis, Roche, Sanofi, Regeneron, UCB, Union Therapeutics, Hexal, Biogen. Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

Source: Allergy

DOI: 10.1111/all.70395

Authors: Thomas Bieber, Felix Lauffer

Institutions: CK-CARE, Ludwig-Maximilians-Universität München

Language: English

Topic: Dermatology and Skin Diseases

Subfield: Dermatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $5,300